Drug Profile
BMS 644950
Alternative Names: BMS-644950Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperlipidaemics; Pyrimidines; Triazoles
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypercholesterolaemia(In volunteers) in USA (PO)
- 15 Apr 2008 Phase-I clinical trials in Hypercholesterolaemia in USA (PO)
- 15 Apr 2008 Pharmacokinetics and pharmacodynamics data from phase I and preclinical trials in Hypercholesterolaemia released by Bristol-Myers Squibb